Date published: 2025-10-19

1-800-457-3801

SCBT Portrait Logo
Seach Input

DAN Inhibitors

DAN inhibitors refer to a class of molecules that specifically interact with the DAN (Differential Screening-selected Gene Aberrative in Neuroblastoma) family proteins. The DAN family, characterized by its cystine knot structure, consists of secreted glycoproteins that regulate the activity of specific members of the TGF-β (Transforming Growth Factor Beta) superfamily, particularly by inhibiting signaling pathways. These proteins are essential modulators of growth factors that influence cellular processes such as proliferation and differentiation. NBL1 (Neuroblastoma Suppressor of Tumorigenicity 1) is a key gene within this family and was one of the first members identified. It encodes a protein that binds and neutralizes certain members of the BMP (Bone Morphogenetic Protein) family, thereby inhibiting their function in cellular signaling.

The inhibition of BMP signaling through DAN family proteins like NBL1 can have a broad impact on cellular processes due to BMP's role in regulating growth, development, and differentiation. DAN inhibitors target the structural interactions between the cystine knot motifs in the DAN protein and the BMP ligands, effectively blocking the downstream signaling pathways. This inhibition is critical in maintaining proper cellular homeostasis and ensuring the appropriate responses to growth factors. The mechanism of DAN inhibitors centers on their ability to prevent BMP ligands from binding to their receptors, modulating the effects that these ligands would otherwise have on cells.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Palbociclib

571190-30-2sc-507366
50 mg
$315.00
(0)

A CDK4/6 inhibitor, potentially affecting the cell cycle and indirectly influencing DAN activity.

Ribociclib

1211441-98-3sc-507367
10 mg
$450.00
(0)

Another CDK4/6 inhibitor, similar to Palbociclib, it may impact the cell cycle pathways.

Abemaciclib

1231929-97-7sc-507342
10 mg
$110.00
(0)

Inhibits CDK4/6, potentially altering cell cycle progression and indirectly affecting DAN signaling.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$112.00
$163.00
$928.00
19
(1)

A MEK inhibitor, which might indirectly affect DAN-related pathways in neuroblastoma.

Selumetinib

606143-52-6sc-364613
sc-364613A
sc-364613B
sc-364613C
sc-364613D
5 mg
10 mg
100 mg
500 mg
1 g
$28.00
$80.00
$412.00
$1860.00
$2962.00
5
(1)

Another MEK inhibitor, potentially influencing pathways associated with DAN.

Vemurafenib

918504-65-1sc-364643
sc-364643A
10 mg
50 mg
$115.00
$415.00
11
(1)

Targets BRAF, which may be involved in pathways relevant to DAN's role in neuroblastoma.

Dabrafenib

1195765-45-7sc-364477
sc-364477A
sc-364477B
sc-364477C
sc-364477D
5 mg
25 mg
50 mg
100 mg
10 g
$138.00
$255.00
$273.00
$403.00
$12240.00
6
(1)

A BRAF inhibitor, potentially affecting signaling pathways related to DAN.

Erlotinib Hydrochloride

183319-69-9sc-202154
sc-202154A
10 mg
25 mg
$74.00
$119.00
33
(1)

An EGFR inhibitor, could indirectly affect cell signaling pathways relevant to DAN.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$62.00
$112.00
$214.00
$342.00
74
(2)

Another EGFR inhibitor, potentially altering signaling pathways associated with DAN.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

Inhibits multiple tyrosine kinases, potentially influencing DAN-related signaling.